There are currently a number of different targeted therapies investigated against ERBB2 [NCT03602079, NCT04466891], FGFR [NCT03773302, NCT02150967, NCT03656536, NCT02150967, NCT03230318], IDH [NCT03212274, NCT03878095, NCT03991832, NCT04521686], and ROS1/ALK [NCT02568267] as either monotherapies or in combination with chemotherapy in clinical trials in CCA. Here, ERBB2 is linked to cholangiocarcinoma.